menu
    • menu
    [{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"A197","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Topical","sponsorNew":"Aramis Biosciences \/ Safar Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"A197","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Dompe farmaceutici","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Dompe farmaceutici"}]

    Find Clinical Drug Pipeline Developments & Deals by Aramis Biosciences

    Menu

    Aramis Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aramis Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aramis Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A197

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dr...

                            Details : A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.

                            Brand Name : A197

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : A197

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aramis Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aramis Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A197

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Safar Partners

                            Deal Size : $10.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

                            Details : Proceeds from the financing will be used to advance the company’s pipeline, including its lead product A197, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment ...

                            Brand Name : A197

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 15, 2021

                            Lead Product(s) : A197

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Safar Partners

                            Deal Size : $10.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth